Cannabinoid receptor 2 deficiency in haematopoietic cells aggravates early atherosclerosis in LDL receptor deficient mice

Open Cardiovascular Medicine Journal

Volumn 5, Issue 1, 2011, Pages 15-21

  Delsing, Dianne J M ^a   Leijten, Frank P ^a   Arts, Karin ^a   van Eenennaam, Hans ^a   Garritsen, Anja ^a   Gijbels, Marion J J ^b   de Winther, Menno P J ^b   van Elsas, Andrea ^a  

^a Department of Immune Therapeutics ^*  (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Cannabinoid receptor; CB2; LDLr mice

Indexed keywords

CANNABINOID 2 RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ATHEROSCLEROSIS; AORTA ROOT; AORTA VALVE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW TRANSPLANTATION; CELL AGGREGATION; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEMATOPOIETIC CELL; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; WILD TYPE;

EID: 80053487797     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010015     Document Type: Article

References (29)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
2. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. Greaves DR, Channon KM. Inflammation and immune responses in atherosclerosis. Trends Immunol 2002; 23: 535-541.
4. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
5. Ashton JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007; 8: 373-384.
6. Pertwee R. The evidence for the existence of cannabinoid receptors. Gen Pharmacol 1993; 24: 811-824.
7. Munro S, Thomas KL, Bu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
8. Kurihara R, Tohyama Y, Matsusaka S, et al. Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil- like HL60 cells and human neutrophils. J Biol Chem 2006; 281: 12908-12918.
9. Jorda MA, Verbakel SE, Valk PJ, et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 2002; 99: 2786-9273.
10. Sacerdote P, Martucci C, Vaccani A, et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL- 10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 2005; 159: 97-105.
11. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-411.
12. Oka S, Wakui J, Gokoh M, Kishimoto S, Sugiura T. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. Eur J Pharmacol 2006; 538: 154-162.
13. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collageninduced arthritis. Arthritis Rheum 2004; 50: 985-998.
14. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434: 782-6.
15. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007; 152: 576-582.
16. Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 2000; 396: 141-9.
17. Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008; 153: 309-318.
18. Gijbels MJ, van der CM, van der Laan LJ, et al. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis 1999; 143: 15-25.
19. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 2005; 85: 9-23.
20. Jiang JLS, Pu J, Han ZH, Hu LH, He B. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res 2009; 81: 805-813.
21. Kishimoto S, Gokoh M, Oka S, et al. 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophagelike cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 2003; 278: 24469-24475.
22. Lunn CA, Fine JS, Rojas-Triana A, et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 2006; 316: 780-8.
23. Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 2008; 153: 299-308.
24. Freeman-Anderson NE, Pickle TG, Netherland CD, Bales A, Buckley NE, Thewke DP. Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterolinduced apoptosis. J Lipid Res 2008; 49: 2338-2346.
25. Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res 2000; 45: 736-746.
26. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-81.
27. Smith SR, Terminelli C, Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 2000; 293: 136-150.
28. Derocq JM, Jbilo O, Bouaboula M, Ségui M, Clère C, Casellas P. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem 2000; 275: 15621-8.
29. Mach F, Steffens S. The role of the endocannabinoid system in atherosclerosis. J Neuroendocrinol 2008; 20 Suppl 1: 53-57.